TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) — Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into a sponsored research agreement with the Terasaki Institute to…


Previous articleNovamind Fast Tracked for Inclusion in Horizons Psychedelic ETF
Next articlePT232 – Dr. Ryan Westrum – Who We Are Without Medicine